Allogene Therapeutics, Inc. (ALLO, Financial) stock experienced significant movement with a 5.02% increase in its price. The stock is currently trading at $2.83 per share with a trading volume of 480,807 shares and a turnover rate of 0.23%. The stock's volatility stands at 4.09%.
Financially, the company reported zero revenue, a net loss of $66.36 million, and earnings per share of -$0.35. Its gross profit is noted at -$3.64 million, with a price-to-earnings ratio of -1.77. Despite these figures, 72% of the 18 institutions that rated the stock recommend buying, while 28% suggest holding, and none advise selling.
Within the biotechnology sector, which has seen an overall decline of 0.19%, other stocks like Bright Minds Biosciences Inc. and Psyence Biomedical Ltd have shown considerable gains. Stocks such as 180 Life Sciences Corp., Quoin Pharmaceuticals Ltd, and Bright Minds Biosciences Inc. have been notably active with high turnover rates and fluctuations.
Allogene Therapeutics Inc is a clinical-stage biotechnology company specializing in immuno-oncology. It focuses on developing genetically engineered allogeneic T-cell products aimed at treating cancer and autoimmune diseases. Their approach, utilizing donor-derived T-cells, aims for broader patient eligibility and scalability. The company's pipeline features ready-made T-cell candidates targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue stems primarily from collaboration and licensing agreements supporting their research and development efforts.
